AU2001270081A1 - Systems and methods for treating a mucosal surface - Google Patents

Systems and methods for treating a mucosal surface

Info

Publication number: AU2001270081A1
Authority: AU; Australia
Prior art keywords: piston; carbon atoms; irm; mucosal surface; amines
Prior art date: 2000-06-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001270081A

Other languages

English (en)

Inventor

John C. Hedenstrom

Michael J. Jozwiakowski

Mark Martinez

Kenneth R. Phares

Kenneth F. Trofatter Jr.

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

3M Innovative Properties Co

Original Assignee

3M Innovative Properties Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-22

Filing date

2001-06-22

Publication date

2002-01-02

2000-09-29 Priority claimed from US09/676,339 external-priority patent/US6486168B1/en

2001-06-22 Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co

2002-01-02 Publication of AU2001270081A1 publication Critical patent/AU2001270081A1/en

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title description 33
-1 imidazoquinoline amines Chemical class 0.000 claims description 73
238000012384 transportation and delivery Methods 0.000 claims description 64
150000001875 compounds Chemical class 0.000 claims description 59
210000003679 cervix uteri Anatomy 0.000 claims description 38
DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 37
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
229940124669 imidazoquinoline Drugs 0.000 claims description 21
239000008194 pharmaceutical composition Substances 0.000 claims description 21
206010008263 Cervical dysplasia Diseases 0.000 claims description 19
230000028993 immune response Effects 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 13
150000001412 amines Chemical class 0.000 claims description 12
239000003607 modifier Substances 0.000 claims description 12
208000007951 cervical intraepithelial neoplasia Diseases 0.000 claims description 9
239000003755 preservative agent Substances 0.000 claims description 7
235000014113 dietary fatty acids Nutrition 0.000 claims description 6
239000000194 fatty acid Substances 0.000 claims description 6
229930195729 fatty acid Natural products 0.000 claims description 6
150000004665 fatty acids Chemical class 0.000 claims description 6
230000002335 preservative effect Effects 0.000 claims description 6
NFYMGJSUKCDVJR-UHFFFAOYSA-N 2-propyl-[1,3]thiazolo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(SC(CCC)=N3)C3=C(N)N=C21 NFYMGJSUKCDVJR-UHFFFAOYSA-N 0.000 claims description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
125000004432 carbon atom Chemical group C* 0.000 description 144
239000000203 mixture Substances 0.000 description 103
238000009472 formulation Methods 0.000 description 94
125000000217 alkyl group Chemical group 0.000 description 62
239000003795 chemical substances by application Substances 0.000 description 59
229910052739 hydrogen Inorganic materials 0.000 description 39
239000001257 hydrogen Substances 0.000 description 39
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 36
229960002751 imiquimod Drugs 0.000 description 35
125000003545 alkoxy group Chemical group 0.000 description 28
239000002831 pharmacologic agent Substances 0.000 description 26
229910052736 halogen Inorganic materials 0.000 description 25
XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 24
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
210000001519 tissue Anatomy 0.000 description 21
125000001424 substituent group Chemical group 0.000 description 20
150000002367 halogens Chemical class 0.000 description 19
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 18
238000011282 treatment Methods 0.000 description 18
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 16
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 15
229920002125 Sokalan® Polymers 0.000 description 15
230000001225 therapeutic effect Effects 0.000 description 15
150000002431 hydrogen Chemical class 0.000 description 14
125000002768 hydroxyalkyl group Chemical group 0.000 description 14
241000701806 Human papillomavirus Species 0.000 description 13
229960001631 carbomer Drugs 0.000 description 13
239000003814 drug Substances 0.000 description 13
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
125000000753 cycloalkyl group Chemical group 0.000 description 11
230000000699 topical effect Effects 0.000 description 11
125000004183 alkoxy alkyl group Chemical group 0.000 description 10
239000012530 fluid Substances 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 9
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 9
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 9
229960002216 methylparaben Drugs 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
210000001215 vagina Anatomy 0.000 description 9
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 8
125000003342 alkenyl group Chemical group 0.000 description 8
229940079593 drug Drugs 0.000 description 8
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 8
235000010199 sorbic acid Nutrition 0.000 description 8
239000004334 sorbic acid Substances 0.000 description 8
229940075582 sorbic acid Drugs 0.000 description 8
238000012360 testing method Methods 0.000 description 8
206010008342 Cervix carcinoma Diseases 0.000 description 7
102000004127 Cytokines Human genes 0.000 description 7
108090000695 Cytokines Proteins 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 7
230000000259 anti-tumor effect Effects 0.000 description 7
230000000840 anti-viral effect Effects 0.000 description 7
201000010881 cervical cancer Diseases 0.000 description 7
210000003811 finger Anatomy 0.000 description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
229960004063 propylene glycol Drugs 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
239000000243 solution Substances 0.000 description 7
241000700159 Rattus Species 0.000 description 6
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 6
125000004423 acyloxy group Chemical group 0.000 description 6
239000012071 phase Substances 0.000 description 6
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 5
108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000011049 filling Methods 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000008213 purified water Substances 0.000 description 5
230000004044 response Effects 0.000 description 5
230000009885 systemic effect Effects 0.000 description 5
210000003813 thumb Anatomy 0.000 description 5
238000011200 topical administration Methods 0.000 description 5
206010058314 Dysplasia Diseases 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
102000014150 Interferons Human genes 0.000 description 4
108010050904 Interferons Proteins 0.000 description 4
102000004889 Interleukin-6 Human genes 0.000 description 4
108090001005 Interleukin-6 Proteins 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
125000005041 acyloxyalkyl group Chemical group 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000011203 carbon fibre reinforced carbon Chemical group 0.000 description 4
239000002738 chelating agent Substances 0.000 description 4
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
229940100601 interleukin-6 Drugs 0.000 description 4
230000007794 irritation Effects 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
229920001993 poloxamer 188 Polymers 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
VFTLXHXYGQSOEN-UHFFFAOYSA-N 1h-imidazo[4,5-b][1,8]naphthyridine Chemical compound C1=CN=C2NC3=NC=NC3=CC2=C1 VFTLXHXYGQSOEN-UHFFFAOYSA-N 0.000 description 3
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical class NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 3
QOOXNMYDCWUEHW-UHFFFAOYSA-N [1,3]oxazolo[4,5-h]quinolin-2-amine Chemical class C1=CC=NC2=C(OC(N)=N3)C3=CC=C21 QOOXNMYDCWUEHW-UHFFFAOYSA-N 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
125000001309 chloro group Chemical group Cl* 0.000 description 3
239000006071 cream Substances 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
229940071106 ethylenediaminetetraacetate Drugs 0.000 description 3
239000011888 foil Substances 0.000 description 3
125000001072 heteroaryl group Chemical group 0.000 description 3
125000000623 heterocyclic group Chemical group 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
230000003308 immunostimulating effect Effects 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
229940079322 interferon Drugs 0.000 description 3
230000003902 lesion Effects 0.000 description 3
238000002483 medication Methods 0.000 description 3
229910021645 metal ion Inorganic materials 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 3
230000035515 penetration Effects 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
239000004033 plastic Substances 0.000 description 3
238000012216 screening Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000829 suppository Substances 0.000 description 3
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 description 2
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000009889 Herpes Simplex Diseases 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
208000009608 Papillomavirus Infections Diseases 0.000 description 2
229920001214 Polysorbate 60 Polymers 0.000 description 2
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
239000004147 Sorbitan trioleate Substances 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000002411 adverse Effects 0.000 description 2
125000004414 alkyl thio group Chemical group 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
125000004965 chloroalkyl group Chemical group 0.000 description 2
238000002573 colposcopy Methods 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
125000003709 fluoroalkyl group Chemical group 0.000 description 2
125000001188 haloalkyl group Chemical group 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
125000005113 hydroxyalkoxy group Chemical group 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
230000000622 irritating effect Effects 0.000 description 2
238000009533 lab test Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000002175 menstrual effect Effects 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000003232 mucoadhesive effect Effects 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
238000011580 nude mouse model Methods 0.000 description 2
239000007764 o/w emulsion Substances 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
238000009595 pap smear Methods 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
229940113124 polysorbate 60 Drugs 0.000 description 2
238000004321 preservation Methods 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
235000013772 propylene glycol Nutrition 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
238000007789 sealing Methods 0.000 description 2
239000001587 sorbitan monostearate Substances 0.000 description 2
235000011076 sorbitan monostearate Nutrition 0.000 description 2
229940035048 sorbitan monostearate Drugs 0.000 description 2
235000019337 sorbitan trioleate Nutrition 0.000 description 2
229960000391 sorbitan trioleate Drugs 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
HQBUPOAKJGJGCD-UHFFFAOYSA-N 3h-imidazo[4,5-c]quinolin-4-amine Chemical class NC1=NC2=CC=CC=C2C2=C1N=CN2 HQBUPOAKJGJGCD-UHFFFAOYSA-N 0.000 description 1
206010059313 Anogenital warts Diseases 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
208000032027 Essential Thrombocythemia Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000019223 Interleukin-1 receptor Human genes 0.000 description 1
108050006617 Interleukin-1 receptor Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical group [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
208000014604 Specific Language disease Diseases 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
201000004201 anogenital venereal wart Diseases 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
201000007201 aphasia Diseases 0.000 description 1
238000004500 asepsis Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013522 chelant Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
229940009662 edetate Drugs 0.000 description 1
229940124274 edetate disodium Drugs 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000013022 formulation composition Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001879 gelation Methods 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000005484 gravity Effects 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000004700 high-density polyethylene Substances 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000000899 immune system response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000001746 injection moulding Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000013532 laser treatment Methods 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
229920000092 linear low density polyethylene Polymers 0.000 description 1
239000004707 linear low-density polyethylene Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
229920001684 low density polyethylene Polymers 0.000 description 1
239000004702 low-density polyethylene Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
WLGDAKIJYPIYLR-UHFFFAOYSA-M octane-1-sulfonate Chemical compound CCCCCCCCS([O-])(=O)=O WLGDAKIJYPIYLR-UHFFFAOYSA-M 0.000 description 1
108091008819 oncoproteins Proteins 0.000 description 1
102000027450 oncoproteins Human genes 0.000 description 1
238000011369 optimal treatment Methods 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229940056099 polyglyceryl-4 oleate Drugs 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
230000022983 regulation of cell cycle Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229910052711 selenium Chemical group 0.000 description 1
239000011669 selenium Chemical group 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000000528 statistical test Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000005017 substituted alkenyl group Chemical group 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
239000011593 sulfur Chemical group 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000003860 topical agent Substances 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
208000024719 uterine cervix neoplasm Diseases 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011800 void material Substances 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Immunology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2001270081A 2000-06-22 2001-06-22 Systems and methods for treating a mucosal surface Abandoned AU2001270081A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US21342000P	2000-06-22	2000-06-22
US60213420		2000-06-22
US09676339		2000-09-29
US09/676,339 US6486168B1 (en)	1999-01-08	2000-09-29	Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
PCT/US2001/019979 WO2001097795A2 (fr)	2000-06-22	2001-06-22	Systemes et procedes de traitement de la surface de muqueuses

Publications (1)

Publication Number	Publication Date
AU2001270081A1 true AU2001270081A1 (en)	2002-01-02

Family

ID=26908067

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2001270081A Abandoned AU2001270081A1 (en)	2000-06-22	2001-06-22	Systems and methods for treating a mucosal surface

Country Status (17)

Country	Link
EP (1)	EP1296644A2 (fr)
JP (1)	JP2004508851A (fr)
CN (1)	CN1273110C (fr)
AU (1)	AU2001270081A1 (fr)
BR (1)	BR0112386A (fr)
CA (1)	CA2410208A1 (fr)
CZ (1)	CZ20024175A3 (fr)
EE (1)	EE200200705A (fr)
HR (1)	HRP20021024A2 (fr)
HU (1)	HUP0301233A2 (fr)
IL (1)	IL153087A0 (fr)
MX (1)	MXPA02012524A (fr)
NO (1)	NO20026067L (fr)
NZ (1)	NZ523073A (fr)
PL (1)	PL361975A1 (fr)
SK (1)	SK17812002A3 (fr)
WO (1)	WO2001097795A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0211649D0 (en)	2002-05-21	2002-07-03	Novartis Ag	Organic compounds
WO2004037175A2 (fr)	2002-10-21	2004-05-06	Mgi Pharma Biologics, Inc.	Compositions et methodes pour traiter une maladie a mediation par le papillomavirus humain (hpv)
AU2004284927A1 (en) *	2003-10-22	2005-05-12	University Hospitals Of Cleveland	Method and apparatus for applying medication to internal tissue
US9248127B2 (en)	2005-02-04	2016-02-02	3M Innovative Properties Company	Aqueous gel formulations containing immune response modifiers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5939090A (en) *	1996-12-03	1999-08-17	3M Innovative Properties Company	Gel formulations for topical drug delivery
SK287112B6 (sk) *	1999-01-08	2009-12-07	3M Innovative Properties Company	Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie

2001
- 2001-06-22 CA CA002410208A patent/CA2410208A1/fr not_active Abandoned
- 2001-06-22 PL PL36197501A patent/PL361975A1/xx not_active Application Discontinuation
- 2001-06-22 IL IL15308701A patent/IL153087A0/xx unknown
- 2001-06-22 EP EP01948622A patent/EP1296644A2/fr not_active Withdrawn
- 2001-06-22 MX MXPA02012524A patent/MXPA02012524A/es active IP Right Grant
- 2001-06-22 NZ NZ523073A patent/NZ523073A/xx unknown
- 2001-06-22 CN CNB018115144A patent/CN1273110C/zh not_active Expired - Fee Related
- 2001-06-22 CZ CZ20024175A patent/CZ20024175A3/cs unknown
- 2001-06-22 HU HU0301233A patent/HUP0301233A2/hu unknown
- 2001-06-22 EE EEP200200705A patent/EE200200705A/xx unknown
- 2001-06-22 HR HR20021024A patent/HRP20021024A2/hr not_active Application Discontinuation
- 2001-06-22 WO PCT/US2001/019979 patent/WO2001097795A2/fr not_active Ceased
- 2001-06-22 BR BR0112386-6A patent/BR0112386A/pt not_active Application Discontinuation
- 2001-06-22 AU AU2001270081A patent/AU2001270081A1/en not_active Abandoned
- 2001-06-22 JP JP2002503272A patent/JP2004508851A/ja not_active Abandoned
- 2001-06-22 SK SK1781-2002A patent/SK17812002A3/sk not_active Application Discontinuation
2002
- 2002-12-17 NO NO20026067A patent/NO20026067L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2001097795A2 (fr)	2001-12-27
CA2410208A1 (fr)	2001-12-27
EP1296644A2 (fr)	2003-04-02
CZ20024175A3 (cs)	2003-06-18
MXPA02012524A (es)	2003-04-10
EE200200705A (et)	2004-08-16
BR0112386A (pt)	2003-06-10
CN1273110C (zh)	2006-09-06
JP2004508851A (ja)	2004-03-25
NO20026067D0 (no)	2002-12-17
IL153087A0 (en)	2003-06-24
PL361975A1 (en)	2004-10-18
SK17812002A3 (sk)	2003-05-02
HRP20021024A2 (en)	2005-02-28
NO20026067L (no)	2003-02-17
NZ523073A (en)	2005-04-29
WO2001097795A3 (fr)	2002-04-04
CN1437463A (zh)	2003-08-20
HUP0301233A2 (hu)	2003-08-28

Publication	Publication Date	Title
US6706728B2 (en)	2004-03-16	Systems and methods for treating a mucosal surface
US6245776B1 (en)	2001-06-12	Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6486168B1 (en)	2002-11-26	Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
EP1495758A2 (fr)	2005-01-12	Formulations et procédés utilisés pour le traitement des états pathologiques des muqueuses au moyen d'un modificateur de la réponse immunitaire
US10071156B2 (en)	2018-09-11	Aqueous gel formulations containing immune response modifiers
US20060216333A1 (en)	2006-09-28	Methods related to the treatment of mucosal associated conditions
US20150314115A1 (en)	2015-11-05	Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
AU2001270081A1 (en)	2002-01-02	Systems and methods for treating a mucosal surface
ZA200300568B (en)	2004-01-22	Systems and methods for treating a mucosal surface.
AU2006252154A1 (en)	2007-01-18	Systems and methods for treating a mucosal surface

Legal Events

Date	Code	Title	Description
2007-02-15	MK5	Application lapsed section 142(2)(e) - patent request and compl. specification not accepted